From Scans to Solutions: Inside Aptium AI's Global Ambitions

Why It Matters

Aptium’s fast‑track, AI‑driven scanning could dramatically lower diabetic foot ulcer rates while creating a scalable, recurring‑revenue med‑tech platform with global market potential.

Key Takeaways

• Aptium’s scanner captures six images instantly, creates 3D model in seconds.
• Started with podiatry to address diabetic foot ulcer market of 500M patients.
• Business model combines hardware sales with per-scan SaaS revenue stream.
• Secured global patents and class‑1 regulatory clearance for rapid rollout.
• Raising $5 M to scale production, target profit within 12 months.

Summary

Aptium AI, an Australian med‑tech firm, unveiled its 4D scanning platform that merges mult‑spectral imaging with AI to produce instant 3D models for clinical use. The company chose podiatry and diabetic foot care as its launch market, citing a global diabetes base of 500 million and a 34% risk of foot ulcers that often lead to amputation. The technology captures six images with a single button press, stitches them into an STL file in seconds, and streams the data to the cloud. Revenue will flow from hardware sales to orthotic labs and a per‑scan SaaS fee, creating a recurring income model. Aptium has filed three core patent families worldwide and the device qualifies as a Class‑1 medical product, allowing self‑declaration rather than costly clinical trials. Executive Chairman Dr. Mel Bridges highlighted the novelty of the scanner, noting an official patent office acknowledgment of its uniqueness. CEO Carl Stubbings projected a global rollout—already securing orders in Europe, the Middle East, India, Japan, Indonesia and prospects in North America and Brazil—while targeting a $5 million raise to build a 300‑500 unit production line. If the rollout proceeds as planned, Aptium expects to become revenue‑neutral within months and profitable within a year, positioning itself as a potential listed company with a market cap of $100‑150 million and opening pathways into surgical planning, industrial safety and other health‑care applications.

Original Description

Artificial intelligence may dominate headlines, but its most immediate impact is increasingly physical. Australian medtech company Aptium AI is a case in point, combining 4D scanning, multispectral imaging and AI to deliver near-instant, high-resolution 3D models for clinical use.

The company’s handheld device captures multiple images in a fraction of a second, stitching them into a precise 3D model that can be used by clinicians to design customised treatments. Aptium AI is initially targeting podiatry, which CEO Carl Stubbings says is a strategic entry point driven by both accessibility and urgent clinical need.

Globally, around 500 million people live with diabetes, a figure expected to rise sharply by 2030. More than a third will develop foot ulcers, a leading cause of lower limb amputations. Aptium AI’s technology aims to intervene early, identifying pressure points and enabling tailored orthotics that reduce the risk of ulcer formation.

Beyond podiatry, Executive Chair Dr Mel Bridges sees significant opportunity across broader healthcare, including surgical planning, as well as industrial applications such as safety monitoring in mining.

Commercially, Aptium AI is pursuing a dual revenue model: upfront hardware sales paired with recurring “pay-per-scan” software income. Early demand is emerging across Europe, the Middle East and India, with further expansion planned into Asia and the Americas.

Currently raising $5 million, the company is focused on scaling manufacturing and building its install base. If successful, management expects to achieve revenue generation within months and profitability within a year of launch, positioning Aptium AI as a potential global leader in advanced imaging technology.